|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
Case report
A rare complication of eculizumab treatment for atypical hemolytic uremic syndrome
Agnieszka Maria Cyran
1, 2
,
Iwona Ogarek
1, 2
,
Joanna Kwinta-Rybicka
1, 2
,
Dorota Drożdż
1, 2
Pediatr Pol 2025; 100 (4)
Online publish date: 2025/11/24
Article file
- A rare complication.pdf
[0.84 MB]
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
1. Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol 2013; 8: 554-562. 2.
Pickering MC, de Jorge EG, Martinez-Barricarte R, Recalde S, Garcia-Layana A, Rose KL, et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007; 204: 1249-1256. 3.
Tempark T, John S, Rerknimitr P, Satapornpong P, Sukasem C. Drug-induced severe cutaneous adverse reactions: insights into clinical presentation, immunopathogenesis, diagnostic methods, treatment, and pharmacogenomics. Front Pharmacol 2022; 13: 832048. 4.
Choudhary S, McLeod M, Torchia D, Romanelli P. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. J Clin Aesthet Dermatol 2013; 6: 31-37. 5.
Wang XF, Bao LR, Hu TL, Xu RF, Gao WN, Wang JY, et al. Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database. Front Pharmacol 2025; 15: 1440907. 6.
Muff-Luett M, Sanderson KR, Engen RM, Zahr RS, Wenderfer SE, Tran CL, et al. Eculizumab exposure in children and young adults: indications, practice patterns, and outcomes − a Pediatric Nephrology Research Consortium study. Pediatr Nephrol 2021; 36: 2349-2360. 7.
Nishimura JI, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, et al. Real-world safety profile qof eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan. Int J Hematol 2023; 118: 419-431. 8.
Sharma R, Romo M, Nelson F. Eculizumab-related drug reaction in a patient with neuromyelitis optica. Clin Case Rep 2023; 11: e6835. 9.
Knoll BM, Letendre L, Steensma DP. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria. Am J Hematol 2008; 83: 881-883. 10.
Röth A, Nishimura JI, Nagy Z, Gaàl-Weisinger J, Panse J, Yoon SS, et al. The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. Blood 2020; 135: 912-920.
Copyright: © 2025 Polish Society of Paediatrics. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
|
POLSKI
